Last 31 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -6.89 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 312.21 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 2.61 | 1.81 | 3.40 | 1.57 | 0.63 | 0.51 | 0.56 | 1.01 | 1.60 | 1.25 | 1.47 | 1.41 | 1.42 | 1.66 | 1.14 | 0.71 | 0.81 | 0.99 | 1.54 | 1.77 | 2.02 |
| — | +258.2% | +509.1% | +54.9% | -60.6% | -59.5% | -62.1% | -28.1% | +12.4% | -25.1% | +29.8% | +97.5% | +75.3% | +67.8% | -26.4% | -59.7% | -59.7% | -30.4% | -75.7% | — | -78.1% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 693.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -8296.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -7615.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -32.3% | -10.5% | -9.8% | -8.5% | -7.8% | -8.0% | -8.2% | -8.1% | -7.2% | -7.4% | -7.3% | -6.3% | -5.6% | -5.3% | -4.8% | -4.2% | -4.2% | -4.3% | -4.4% | -4.5% | -3.8% |
| — | -31.2% | -18.3% | -3.8% | -8.1% | -7.8% | -13.3% | -29.8% | -28.0% | -39.5% | -50.4% | -49.8% | -32.0% | -24.6% | -9.5% | +7.0% | -12.3% | +7.9% | +47.7% | +51.3% | +30.9% | |
| ROA | -27.2% | -8.5% | -8.0% | -7.0% | -6.6% | -6.8% | -7.1% | -7.0% | -6.2% | -6.4% | -6.3% | -5.5% | -4.9% | -4.7% | -4.3% | -3.8% | -3.8% | -3.9% | -4.0% | -4.3% | -3.7% |
| — | -24.3% | -12.8% | -0.4% | -6.1% | -6.3% | -12.0% | -28.3% | -26.3% | -37.3% | -46.6% | -44.4% | -27.2% | -20.3% | -6.8% | +11.2% | -3.3% | +14.9% | -83.4% | +6.1% | +29.2% | |
| ROIC | -26.0% | -7.8% | -7.3% | -6.7% | -6.7% | -7.0% | -7.0% | -6.5% | -5.8% | -6.2% | -6.0% | -5.8% | -5.8% | -5.6% | -5.6% | -6.2% | -7.4% | -6.7% | -6.0% | -6.3% | -7.4% |
| — | -10.7% | -3.2% | -2.9% | -15.2% | -12.6% | -16.7% | -12.3% | +0.0% | -10.7% | -7.5% | +6.4% | +21.1% | +15.6% | +6.9% | +2.3% | +1.1% | +48.7% | — | +34.3% | -78.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.19 | 0.21 | 0.20 | 0.19 | 0.16 | 0.16 | 0.15 | 0.15 | 0.14 | 0.14 | 0.13 | 0.13 | 0.13 | 0.13 | 0.12 | 0.10 | 0.09 | 0.09 | 0.09 | 0.08 | 0.01 |
| — | +36.3% | +32.5% | +31.0% | +13.0% | +12.3% | +12.0% | +11.9% | +9.9% | +10.1% | +9.7% | +35.5% | +43.4% | +43.5% | +43.0% | +16.6% | +839.6% | +4887.2% | +382.7% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 13.33 | 10.14 | 11.85 | 13.33 | 14.95 | 18.52 | 17.36 | 17.40 | 16.65 | 19.69 | 20.09 | 19.39 | 21.00 | 21.13 | 21.50 | 27.57 | 40.60 | 49.75 | 51.06 | 60.09 | 83.68 |
| — | -45.2% | -31.8% | -23.4% | -10.2% | -5.9% | -13.6% | -10.2% | -20.7% | -6.8% | -6.6% | -29.7% | -48.3% | -57.5% | -57.9% | -54.1% | -51.5% | -57.1% | +232.7% | +133.5% | +650.5% | |
| Quick Ratio | 13.33 | 10.14 | 11.85 | 13.33 | 14.95 | 18.52 | 17.36 | 17.40 | 16.65 | 19.69 | 20.09 | 19.39 | 21.00 | 21.13 | 21.50 | 27.57 | 40.60 | 49.75 | 51.06 | 60.09 | 83.68 |
| — | -45.2% | -31.8% | -23.4% | -10.2% | -5.9% | -13.6% | -10.2% | -20.7% | -6.8% | -6.6% | -29.7% | -48.3% | -57.5% | -57.9% | -54.1% | -51.5% | -57.1% | +232.7% | +133.5% | +650.5% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 31 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NAUT stock.
Nautilus Biotechnolgy, Inc.'s current P/E is -6.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nautilus Biotechnolgy, Inc.'s business trajectory between earnings reports.